Gentian Diagnostics ASA

Oslo Stock Exchange GENT.OL

Gentian Diagnostics ASA Shareholders' Equity for the year ending December 31, 2023: USD 14.40 M

Gentian Diagnostics ASA Shareholders' Equity is USD 14.40 M for the year ending December 31, 2023, a -8.41% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.
  • Gentian Diagnostics ASA Shareholders' Equity for the year ending December 31, 2022 was USD 15.72 M, a -20.59% change year over year.
  • Gentian Diagnostics ASA Shareholders' Equity for the year ending December 31, 2021 was USD 19.79 M, a -12.71% change year over year.
  • Gentian Diagnostics ASA Shareholders' Equity for the year ending December 31, 2020 was USD 22.68 M, a -4.37% change year over year.
  • Gentian Diagnostics ASA Shareholders' Equity for the year ending December 31, 2019 was USD 23.71 M, a -16.58% change year over year.
Key data
Date Shareholders' Equity Minority Interest Total Equity Total Stockholders Equity and Liabilities
Market news
Loading...
SV Wall Street
Oslo Stock Exchange: GENT.OL

Gentian Diagnostics ASA

CEO Mr. Njaal Kind
IPO Date Dec. 14, 2016
Location Norway
Headquarters Bjørnåsveien 5
Employees 58
Sector Healthcare
Industries
Description

Gentian Diagnostics ASA researches, develops, and produces biochemical reagents for use in medical diagnostics and research in Europe, Asia, and the United States. It offers in-vitro diagnostic reagents for clinical chemistry analyzers. The company's products include the gentian calprotectin immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Cystatin C, a superior GFR marker for the diagnosis and therapeutic control of renal function; NT-proBNP Immunoassay for diagnosis, monitoring, and assessment of severity in individuals suspected of having congestive heart failure; and Canine c-reactive protein (CRP) immunoassay, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine CRP in dog plasma and serum. It also provides turbidimetric SARS-CoV-2 total antibody immunoassay, a quantitative antibody test for detecting antibodies targeting the S1-subunit. The company was incorporated in 2001 and is headquartered in Moss, Norway.

Similar companies

GOD.OL

Goodtech ASA

USD 0.85

0.36%

PHO.OL

Photocure ASA

USD 5.25

2.05%

BGBIO.OL

BerGenBio ASA

USD 0.73

3.02%

ULTI.OL

Ultimovacs ASA

USD 0.19

-0.80%

StockViz Staff

February 7, 2025

Any question? Send us an email